Portfolio Lab

Merck & Co., Inc.

  • Stock
  • Ticker MRK
  • ISIN US58933Y1055
  • NYSE

Health care · Pharmaceuticals · USA

$133.72 +0.69%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Merck & Co., Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

MRKGlobal equities (VT)

$10,000 grew to $30,521. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −43.5% in 05/2025, measured from the peak in 06/2024. It took 24 months to get back to the old peak.

1-year return
+45.0%
5-year return p.a.
+14.1%
10-year return p.a.
+11.8%
Volatility p.a.
21.6%
Largest decline
−43.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue15,62415,52915,80617,27616,40016,28616,60718,085
Gross profit11,79612,11012,24913,42110,84912,09112,21213,193
Net income3,7435,0794,4275,7852,963-4,240-1,3355,065
Earnings per share1.482.011.762.321.20-1.72-0.542.04
Balance sheet
Total assets117,106115,122117,523129,546136,866128,685129,802132,773
Liabilities70,73466,72268,46377,63984,20482,75487,81887,827
Equity46,31348,33548,99351,85052,60645,87841,93344,893
Cash13,2428,6298,00718,16914,5655,3276,8499,550
Long-term debt34,46233,48433,96839,96946,75046,67351,08149,689
Cash flow
Operating cash flow3,4502,5003,2937,8222,8573,9185,3706,558
Capital expenditure-937-1,328-764-987-1,033-991-893-1,040
Free cash flow2,5131,1722,5296,8351,8242,9274,4775,518

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2022 at +49.4%, weakest 2020 at −7.2%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$2.04
7 Aug 2026−$0.54
4 May 2026−$1.72
24 Feb 2026$1.20
5 Nov 2025$2.32
5 Aug 2025$1.76
2 May 2025$2.01
25 Feb 2025$1.48
6 Nov 2024$1.24
5 Aug 2024$2.14
3 May 2024$1.87
26 Feb 2024−$0.48

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€299bn
Market cap in trading currency
$330bn
Enterprise value
$374bn
P/E
136.4
P/S
4.89
P/B
7.34
EV/Sales
5.55
EV/EBITDA
36.9
Earnings yield
0.7%
FCF yield
4.5%

Results (last four quarters)

Revenue
$67.4bn
Gross profit
$48.3bn
EBITDA
$10.1bn
Net income
$2.45bn
Earnings per share
$0.98
Revenue per share
$27.33
Revenue growth
+4.7%
Earnings growth
−12.4%

Profitability

Gross margin
71.8%
Operating margin
10.0%
Net margin
3.6%
Return on equity
5.1%
Return on assets
1.8%

Balance sheet and cash flow

Cash
$9.65bn
Cash per share
$3.91
Financial debt
$53.8bn
Debt/equity %
120
Current ratio
1.35
Book value per share
$18.21
Operating cash flow
$18.7bn
Free cash flow
$14.7bn

Dividend

Dividend yield
2.54%
Dividend (12 months)
$3.40
Yield (12 months)
2.54%
Payout ratio
347%
Ex-dividend date
15 Sep 2026

Shares and trading

Shares outstanding
2.47bn
Volume
15.5m
Avg. volume 3 months
10.3m
Relative volume
1.6

Price and technicals

Price
$133.72
1 day
+0.7%
52-week high
$156.45
52-week low
$94.97
Distance to 52-week high
−14.5%
Distance to 52-week low
+40.8%
Distance to 50-day line
−8.0%
Distance to 200-day line
+3.5%
RSI (14)
34
Volatility 1M
34.3%

Performance

1 week
−9.5%
1 month
−9.2%
3 months
−11.2%
6 months
+9.2%
YTD
+27.0%
1 year
+40.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has MRK performed since 11/2016?

$10,000 grew to $30,521 by 20 Nov 2026, which is +11.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is MRK?

Volatility was 21.6% per year, measured on monthly returns. The largest decline from a peak was −43.5%, with the low in 05/2025.

How does MRK compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, MRK returned +11.8% at 21.6%. The correlation of monthly returns was 0.24; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Merck & Co., Inc. (MRK): Return and risk | Portfolio Lab